Heterozygous PU.1 mutations are associated with acute myeloid leukemia

被引：20

作者：

Mueller, BU ^{[1
]}

Pabst, T ^{[1
]}

Osato, M ^{[1
]}

Asou, N ^{[1
]}

Johansen, LM ^{[1
]}

Minden, MD ^{[1
]}

Behre, G ^{[1
]}

Hiddemann, W ^{[1
]}

Ito, Y ^{[1
]}

Tenen, DG ^{[1
]}

机构：

[1] Harvard Univ, Inst Med, Boston, MA 02115 USA

来源：

BLOOD | 2003年 / 101卷 / 05期

关键词：

D O I：

10.1182/blood-2002-12-3903

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2074 / 2074

页数：1

共 8 条

[1]

BOMBART AF, 2002, BLOOD, V99, P1332

[2] Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)? [J].

Lamandin, C ;

Sagot, C ;

Roumier, C ;

Lepelley, P ;

De Botton, S ;

Cosson, A ;

Fenaux, P ;

Preudhomme, C .

BLOOD, 2002, 100 (13) :4680-4681

[3] Heterozygous PU.1 mutations are associated with acute myeloid leukemia [J].

Mueller, BU ;

Pabst, T ;

Osato, M ;

Asou, N ;

Johansen, LM ;

Minden, MD ;

Behre, G ;

Hiddemann, W ;

Ito, Y ;

Tenen, DG .

BLOOD, 2002, 100 (03) :998-1007

[4] Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia [J].

Pabst, T ;

Mueller, BU ;

Zhang, P ;

Radomska, HS ;

Narravula, S ;

Schnittger, S ;

Behre, G ;

Hiddemann, W ;

Tenen, DG .

NATURE GENETICS, 2001, 27 (03) :263-270

[5] AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia [J].

Pabst, T ;

Mueller, BU ;

Harakawa, N ;

Schoch, C ;

Haferlach, T ;

Behre, G ;

Hiddemann, W ;

Zhang, DE ;

Tenen, DG .

NATURE MEDICINE, 2001, 7 (04) :444-451

[6] Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia:: a study from the Acute Leukemia French Association (ALFA) [J].

Preudhomme, C ;

Sagot, C ;

Boissel, N ;

Cayuela, JM ;

Tigaud, I ;

de Botton, S ;

Thomas, X ;

Raffoux, E ;

Lamandin, C ;

Castaigne, S ;

Fenaux, P ;

Dombret, H .

BLOOD, 2002, 100 (08) :2717-2723

[7] The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia [J].

Vangala, RK ;

Heiss-Neumann, MS ;

Rangatia, JS ;

Singh, SM ;

Schoch, C ;

Tenen, DG ;

Hiddemann, W ;

Behre, G .

BLOOD, 2003, 101 (01) :270-277

[8] The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-α, inhibits C/EBP-α-dependent transcription, and blocks granulocytic differentiation [J].

Westendorf, JJ ;

Yamamato, CM ;

Lenny, N ;

Downing, JR ;

Selsted, ME ;

Hiebert, SW .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :322-333

← 1 →